抗线粒体抗体作为儿童期起病系统性红斑狼疮疾病活动度标志物的纵向队列研究
该纵向队列研究前瞻性纳入29例儿童期起病系统性红斑狼疮(cSLE)患者,在两个时间点(活动期SLEDAI≥4与临床静止期SLEDAI≤4)检测血清抗线粒体抗体(AMA)IgG、IgM、IgA与IFNα2水平。活动期至静止期AMA-IgG下降(P=0.0426),活动期AMA-IgG与SLEDAI(ρ=0.41,P=0.026)及抗dsDNA(ρ=0.66,P=0.0001)正相关,AMA-IgM随疾病活动度波动(P=0.0065),AMA-IgA保持稳定。
要点
- 活动期至静止期AMA-IgG下降(P=0.0426),与SLEDAI及抗dsDNA正相关。
- AMA-IgM随疾病活动度波动(P=0.0065),AMA-IgA保持稳定。
- 活动期AMA-IgG和IgM与IFNα2水平相关(ρ=0.729,P<0.0001;ρ=0.631,P=0.001)。
核心结论
- AMA-IgG emerged as a promising biomarker of disease activity in cSLE,其升高与IFNα2表达升高一致。
研究设计与样本
- 前瞻性纵向队列研究,纳入29例cSLE患者,在两个时间点采集血清:TP-1为活动期(SLEDAI≥4),TP-2为临床静止期(SLEDAI≤4)。
- 以流式细胞术检测血清IgG、IgM、IgA与人线粒体的结合,以单分子阵列技术检测血清IFNα2水平。
主要发现
- 诊断时中位年龄为14.9±3.6岁;TP-1中位SLEDAI为9.5、泼尼松剂量为0.43 mg/kg/day,TP-2分别为2和0.14 mg/kg/day。
- TP-1与TP-2之间的中位时间间隔为6±3.7个月。
- AMA-IgG从TP-1至TP-2下降(P=0.0426),在TP-1与SLEDAI正相关(ρ=0.41,P=0.026)、与抗dsDNA正相关(ρ=0.66,P=0.0001)。
- AMA-IgM随疾病活动度波动(P=0.0065),AMA-IgA保持稳定。
- 活动期AMA-IgG与IFNα2水平相关(ρ=0.729,P<0.0001),AMA-IgM与IFNα2水平相关(ρ=0.631,P=0.001)。
临床怎么用
- 原文结论认为AMA-IgG是cSLE疾病活动度有前景的生物标志物,其升高与IFNα2表达升高一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mitochondria are prominent antigenic sources, capable of triggering IFN-induced inflammatory pathways in SLE. Recent studies suggest presence of AMA in LN patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data on the potential utility of AMA as a biomarker in cSLE. METHODS: Human mitochondria were incubated with serum, and IgG, IgM and IgA binding assessed by flow cytometry. Sera were obtained prospectively from 29 cSLE patients, at two different timepoints (TP), the first (TP-1) representing a state of active disease (SLEDAI ≥4), and the second (TP-2), of clinically quiescent disease (SLEDAI ≤4). IFNα2 serum levels were assessed by single-molecule array. RESULTS: Median age at disease diagnosis was 14.9 ± 3.6 years. Median SLEDAI and prednisone dose were 9.5 and 0.43 mg/kg/day at TP-1, and 2 and 0.14 mg/kg/day at TP-2. Median time interval between TP-1 and TP-2 was of 6 ± 3.7 months. AMA-IgG decreased between TP-1 and TP-2 (P = 0.0426), and correlated positively with SLEDAI (ρ = 0.41, P = 0.026) and anti-dsDNA (ρ = 0.66, P = 0.0001) at TP-1. AMA-IgM oscillated according to disease activity (P = 0.0065), while AMA-IgA remained stable. AMA-IgG and -IgM correlated with IFNα2 levels (ρ = 0.729, P < 0.0001, and ρ = 0.631, P = 0.001, respectively) during active disease. CONCLUSION: AMA-IgG emerges as a promising biomarker of disease activity in cSLE, and its increase is in alignment with elevated IFNα2 expression.
引用
- Barguil Macêdo M, Wahadat MJ, Björk A, et al. Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study. Rheumatology (Oxford). 2025. PMID: 40408235. doi:10.1093/rheumatology/keaf275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。